Nazione: Regno Unito
Lingua: inglese
Fonte: VMD (Veterinary Medicines Directorate)
Canine adenovirus, Canine distemper virus, Canine parainfluenza virus, Canine parvovirus
Boehringer Ingelheim Animal Health UK Ltd
QI07AD04
Canine adenovirus, Canine distemper virus, Canine parainfluenza virus, Canine parvovirus
Lyophilisate for suspension for injection
POM-V - Prescription Only Medicine – Veterinarian
Dogs
Live Viral Vaccine
Authorized
1997-06-19
Revised: May 2020 AN: 01998/2019 Page 1 of 6 SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE VETERINARY MEDICINAL PRODUCT Eurican DHPPi lyophilisate for suspension for injection 2. QUALITATIVE AND QUANTITATIVE COMPOSITION One dose of lyophilisate contains: Attenuated Canine Distemper virus, MINIMUM MAXIMUM STRAIN BA5 10 4.0 CCID50* 10 6.0 CCID50* Attenuated Canine Adenovirus type 2, STRAIN DK13 10 2.5 CCID50* 10 6.3 CCID50* Attenuated Canine Parvovirus type 2, STRAIN CAG2 10 4.9 CCID50* 10 7.1 CCID50* Attenuated Canine Parainfluenza virus type 2, Strain CGF 2004/75 10 4.7 CCID50* 10 7.1 CCID50* (* CCID50: 50% CELL CULTURE INFECTIVE DOSE) For the full list of excipients, see section 6.1. 3. PHARMACEUTICAL FORM Beige to pale yellow lyophilisate for suspension for injection. 4. CLINICAL PARTICULARS 4.1 TARGET SPECIES Dogs. 4.2 INDICATIONS FOR USE, SPECIFYING THE TARGET SPECIES Active immunisation of dogs to: - prevent mortality and clinical signs caused by canine distemper virus (CDV), - prevent mortality and clinical signs caused by infectious canine hepatitis virus (CAV), - reduce viral excretion during respiratory disease caused by canine Revised: May 2020 AN: 01998/2019 Page 2 of 6 adenovirus type 2 (CAV-2), - prevent mortality, clinical signs and viral excretion caused by canine parvovirus (CPV)*, - reduce viral excretion caused by canine parainfluenza virus type 2 (CPiV), Onset of immunity: 2 weeks for all strains Duration of immunity: at least one year after the second injection of the primary vaccination course for all strains. Current available challenge and serological data show that protection for distemper virus, adenovirus and parvovirus* lasts for 2 years after primary vaccination course followed by a first annual booster. Any decision to adapt the vaccination schedule of this veterinary medicinal product needs to be made on a case by case basis, taking into account the vaccination history of the dog and the epidemiological context. *Protection has been demonstrated against canine parvovirus type 2a, Leggi il documento completo